Wuxin Technology declared the first clinical study on the safety of electronic cigarettes in China

On February 7, the clinical study on the safety of e-cigarettes initiated by Fog core technology (RELX Yueke) has been successfully registered in the First Level Institution of the World Health Organization's International Clinical Trial Registration Platform - China Clinical Trial Registration Center (ChiCTR).

According to Wuxin Technology, this is the first clinical research focusing on "e-cigarette safety" in China, and it is also the second clinical research project initiated by the company, which is undertaken by Sun Yat-sen University - Fogcore Technology Atomization Product Evaluation Laboratory. The laboratory is the first full-process research platform covering non-clinical to clinical research stages in the field of atomization science in China.

Zhong Guoping, the person in charge of the above project and deputy director of the Atomization Product Evaluation Laboratory of Sun Yat-sen University-Fog Core Technology, introduced that the study intends to recruit 36 healthy subjects with smoking habits to randomly group and observe the short-term effects of different products on the respiratory function and cardiovascular function of subjects.

It is reported that clinical research is usually used for new drug development, through trials in subjects, to evaluate the safety and efficacy of drugs. Previously, Wuxin Technology has confirmed the safety of related products through a large number of physical and chemical, cellular and animal research. With the deepening of global e-cigarette scientific research to clinical research, Wuxin Technology has taken the lead in launching relevant clinical research projects in China to further verify the safety of e-cigarettes.

At present, the domestic e-cigarette scientific research system is not perfect. With the e-cigarette industry included in the legal and standardized track, ensuring quality and security, strengthening basic research on atomization science, and safeguarding the interests of consumers have become a must for the healthy development of the industry.

Since 2020, Wuxin Technology has adopted the "1+4" scientific research path to conduct systematic scientific evaluation of e-cigarettes through "safety quality + physical and chemical research, toxicological research, clinical research, and long-term impact research". At present, Fogcore Technology has a number of professional experiments such as physical and chemical laboratories and life science laboratories, and has established cooperation in different dimensions with 8 universities, 2 hospitals, 10 scientific research and commissioned research institutions.

Wen Yilong, co-founder of Wuxin Technology and head of R&D and supply chain, said: "As the first electronic cigarette brand in China to carry out systematic research using modern medicine, toxicology and other methods, the company will continue to invest in scientific research and drive the development of industry standards. ”